Clinical-stage biopharmaceutical company Entrada Therapeutics Inc. (TRDA) has been steadily progressing its pipeline of therapies for neuromuscular diseases, with several key milestones expected in 2026. The company's focus on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) positions it at the forefront of innovation in rare disease treatment.
Key Catalysts Ahead
• ELEVATE-44-201 data from first patient cohort expected in Q2 2026.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.